MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients

Completed
Conditions
Candidiasis
First Posted Date
2016-01-28
Last Posted Date
2020-12-07
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
20
Registration Number
NCT02666716
Locations
🇳🇱

Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands

🇳🇱

Radboud university medical center, Nijmegen, Netherlands

🇳🇱

University Medical Center Utrecht, Utrecht, Netherlands

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

Phase 4
Terminated
Conditions
Coccidioidomycosis
Interventions
Other: Placebo
First Posted Date
2016-01-26
Last Posted Date
2019-07-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
72
Registration Number
NCT02663674
Locations
🇺🇸

UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States

🇺🇸

Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States

and more 6 locations

Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS

Not Applicable
Conditions
Cryptococcal Meningitis
Interventions
Drug: Antiretroviral therapy
First Posted Date
2015-12-08
Last Posted Date
2018-03-15
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
186
Registration Number
NCT02624453
Locations
🇨🇲

Day Hospital of the Yaounde Central Hospital, Yaounde, Central Region, Cameroon

Vietnam Cryptococcal Retention in Care Study Version 1.0

Conditions
Meningitis, Cryptococcal
Central Nervous System Fungal Infections
Meningitis, Fungal
Central Nervous System Infections
Interventions
First Posted Date
2015-01-08
Last Posted Date
2017-09-13
Lead Sponsor
National Hospital for Tropical Diseases, Hanoi, Vietnam
Target Recruit Count
2612
Registration Number
NCT02334670
Locations
🇻🇳

National Hospital for Tropical Diseases, Hanoi, Vietnam

Drug-Drug Interaction Study in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-10-27
Last Posted Date
2014-10-27
Lead Sponsor
Kowa Research Institute, Inc.
Target Recruit Count
20
Registration Number
NCT02275975
Locations
🇺🇸

PPD, Austin, Texas, United States

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Phase 2
Completed
Conditions
Mycoses
Candidiasis, Invasive
Candidemia
Interventions
First Posted Date
2014-09-19
Last Posted Date
2024-06-25
Lead Sponsor
Scynexis, Inc.
Target Recruit Count
27
Registration Number
NCT02244606
Locations
🇺🇸

University of Texas Health Science Center at Houston, Houston, Texas, United States

🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

South Texas Veterans Healthcare System, San Antonio, Texas, United States

and more 27 locations

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: PF-06647020 Q3W
Drug: PF-06647020 Q2W
Drug: PF-06647020 combined with Avelumab
First Posted Date
2014-08-22
Last Posted Date
2020-12-17
Lead Sponsor
Pfizer
Target Recruit Count
138
Registration Number
NCT02222922
Locations
🇺🇸

Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States

🇺🇸

Stanford Cancer Center, Stanford, California, United States

🇺🇸

Stanford Hospital and Clinics, Stanford, California, United States

and more 13 locations

Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-21
Last Posted Date
2014-07-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
20
Registration Number
NCT02195466

Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients

Phase 4
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02181946
© Copyright 2025. All Rights Reserved by MedPath